<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1644">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02564692</url>
  </required_header>
  <id_info>
    <org_study_id>APR-001</org_study_id>
    <nct_id>NCT02564692</nct_id>
  </id_info>
  <brief_title>GeneMatch: A Program of the Alzheimer's Prevention Registry to Match Individuals to Studies Based on Apolipoprotein E (APOE) Genotype</brief_title>
  <official_title>Alzheimer's Prevention Registry GeneMatch Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Banner Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Banner Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the Alzheimer's Prevention Registry GeneMatch program is to identify a large&#xD;
      group of people interested in participating in research studies or clinical trials based in&#xD;
      part on their genetic background. This genetic information will be used to match interested&#xD;
      individuals to studies, providing a recruitment resource to the Alzheimer's scientific&#xD;
      community. Interested individuals should visit www.endALZnow.org/GeneMatch to join the&#xD;
      GeneMatch program.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objectives of the Alzheimer's Prevention Registry GeneMatch program are to (1)&#xD;
      identify and characterize a large cohort of people who are interested in, and may be eligible&#xD;
      to participate in, current and future preclinical Alzheimer's disease research studies and&#xD;
      clinical trials based on their genetic background, and (2) provide information to these&#xD;
      individuals about research studies for which they may be eligible, based in part on their&#xD;
      genetic background. Cognitively unimpaired individuals age 50 to 90, inclusive, are eligible&#xD;
      to enroll in GeneMatch. GeneMatch will provide participants with a genetic sample kit (a&#xD;
      cheek swab) to test for a specific gene called apolipoproteins E (APOE). GeneMatch does not&#xD;
      disclose the results of the APOE test to participants. GeneMatch may use the APOE test&#xD;
      results to match participants to research studies. Participants are under no obligation to&#xD;
      pursue these study opportunities.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">December 2030</completion_date>
  <primary_completion_date type="Anticipated">December 2030</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>15 Years</target_duration>
  <primary_outcome>
    <measure>Number of individuals who enroll in GeneMatch</measure>
    <time_frame>15 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of individuals referred to research studies</measure>
    <time_frame>15 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of individuals who enroll in research studies</measure>
    <time_frame>15 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">500000</enrollment>
  <condition>Alzheimer Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        This large research study will ultimately enroll 500,000 adults. We will recruit subjects&#xD;
        from all over the United States, as everything is done via email, mail, or/and phone.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 50-90, inclusive&#xD;
&#xD;
          -  Provide basic demographic, medical history, and contact information&#xD;
&#xD;
          -  Consent to APOE genotyping without receiving results&#xD;
&#xD;
          -  Live in the United States&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to comply with this project's protocol requirements&#xD;
&#xD;
          -  Self-reported diagnosis of dementia or any other objective cognitive impairment&#xD;
             syndrome&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica B Langbaum, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Banner Alzheimer's Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Gordon, MS</last_name>
    <phone>1-888-STOP-ALZ</phone>
    <email>GeneMatch@endALZnow.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banner Alzheimer's Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Gordon</last_name>
      <email>GeneMatch@endalznow.org</email>
    </contact>
    <investigator>
      <last_name>Jessica B Langbaum, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Langbaum JB, Karlawish J, Roberts JS, Wood EM, Bradbury A, High N, Walsh TL, Gordon D, Aggarwal R, Davis P, Stowell C, Trisko L, Langlois CM, Reiman EM, Tariot PN. GeneMatch: A novel recruitment registry using at-home APOE genotyping to enhance referrals to Alzheimer's prevention studies. Alzheimers Dement. 2019 Apr;15(4):515-524. doi: 10.1016/j.jalz.2018.12.007. Epub 2019 Feb 13.</citation>
    <PMID>30772251</PMID>
  </results_reference>
  <verification_date>July 2022</verification_date>
  <study_first_submitted>September 29, 2015</study_first_submitted>
  <study_first_submitted_qc>September 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2015</study_first_posted>
  <last_update_submitted>July 18, 2022</last_update_submitted>
  <last_update_submitted_qc>July 18, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Banner Health</investigator_affiliation>
    <investigator_full_name>Jessica Langbaum, PhD</investigator_full_name>
    <investigator_title>Director, Alzheimer's Prevention Initiative</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

